Clinical trial
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or…
NCT00023933 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00023933 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer |
| Official title | Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Drug |
| Interventions | iodine I 131 monoclonal antibody CC49-deltaCH2 |
| Enrollment | 15 |
| Start date | Oct 1, 2001 |
| Primary completion | Jul 1, 2005 |
| First posted | Jun 20, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: